AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Avalo Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001V1GPQ9
6.93▼ 0.52 (-6.98%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
7.45
Day's Range
6.53 – 7.50
52-Week Range
6.53 – 24.27
Volume
4.5M
Avg Volume
2.1M
Share Statistics
Shares Outstanding
Employees
33
Exchange
XNAS
Listed
2015-11-13
Share count as of August 3, 2026

Avalo Therapeutics, Inc. Common Stock (AVTX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Avalo Therapeutics, Inc. Common Stock (AVTX)
What is Avalo Therapeutics, Inc. Common Stock's Market Cap?
Avalo Therapeutics, Inc. Common Stock's Market Cap is $371.7M, based on as-reported figures from SEC (XBRL) filings.
What is Avalo Therapeutics, Inc. Common Stock's Enterprise Value?
Avalo Therapeutics, Inc. Common Stock's Enterprise Value is -$28.6M, based on as-reported figures from SEC (XBRL) filings.
What is Avalo Therapeutics, Inc. Common Stock's Price / Sales?
Avalo Therapeutics, Inc. Common Stock's Price / Sales is 6299.3×, based on as-reported figures from SEC (XBRL) filings.
What is Avalo Therapeutics, Inc. Common Stock's EV / Revenue?
Avalo Therapeutics, Inc. Common Stock's EV / Revenue is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Avalo Therapeutics, Inc. Common Stock's EV / EBITDA?
Avalo Therapeutics, Inc. Common Stock's EV / EBITDA is 0.3×, based on as-reported figures from SEC (XBRL) filings.
What is Avalo Therapeutics, Inc. Common Stock's Revenue (TTM)?
Avalo Therapeutics, Inc. Common Stock's Revenue (TTM) is $59.0K, based on as-reported figures from SEC (XBRL) filings.
What is Avalo Therapeutics, Inc. Common Stock's Net Income (TTM)?
Avalo Therapeutics, Inc. Common Stock's Net Income (TTM) is -$100.3M, based on as-reported figures from SEC (XBRL) filings.
What is Avalo Therapeutics, Inc. Common Stock's EBITDA?
Avalo Therapeutics, Inc. Common Stock's EBITDA is -$91.3M, based on as-reported figures from SEC (XBRL) filings.
What is Avalo Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Avalo Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -1.87, based on as-reported figures from SEC (XBRL) filings.
What is Avalo Therapeutics, Inc. Common Stock's EBITDA Margin?
Avalo Therapeutics, Inc. Common Stock's EBITDA Margin is -154662.7%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · AVTXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other (expense) income:
Change in fair value of derivative liability
Change in fair value of contingent consideration———
Interest income, net
Total other (expense) income, net
Loss before taxes
Income tax expense
Net loss
Net loss per share of common stock - basic (in dollars per share)—
Net loss per share of common stock - diluted (in dollars per share)—